Dermira, Inc. is a biopharmaceutical company established in 2010, with its headquarters in the United States. The company is dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions. Dermira is committed to understanding and addressing the needs of both patients and physicians, and using its experience and insight to identify and develop leading-edge medical dermatology clinical programs. The company aims to serve as the bridge between unmet patient needs and the significant scientific advances being made in understanding skin biology. This dedication has been recognized with a substantial $149.50MPost-IPO Equity investment on 19 March 2019. Despite not specifying the investors, this investment undoubtedly reflects the confidence of the investment community in Dermira’s innovative approach to addressing chronic skin conditions. Their work in the Biopharma, Biotechnology, and Pharmaceutical industries signifies strong potential for growth and impact in the healthcare sector. For further details, visit Dermira.com and review their community guidelines: https://bit.ly/2rH5IuL.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Post-IPO Equity | $149.50M | - | 19 Mar 2019 | |
| Post-IPO Equity | $1.00M | - | 28 Dec 2018 | |
| Post-IPO Debt | $125.00M | 1 |
|
04 Dec 2018 |
| Post-IPO Equity | $75.00M | - | 07 Nov 2018 | |
| Post-IPO Equity | $500.00K | - | 15 Dec 2017 |
No recent news or press coverage available for Dermira, Inc..
We care about your data, and we'd love to use cookies make your experience better.
